Spotlight on Formulary Management

[F1] Hemophilia Management – Emerging Therapies and Payer Strategies

ACPE UAN: 0233-0000-19-018-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

• 

  Edmund J. Pezalla, MD, MPH

  CEO and Consultant
  Enlightenment Bioconsult, LLC
  Wethersfield, Connecticut
• 

  Michelle Rice

  Senior Vice President of External Affairs
  National Hemophilia Foundation
  Indianapolis, Indiana

Moderator(s)

• JB

  John Barrett, RPh, MBA

  Vice President, Business Development and Account Management
  PerformRx
  Philadelphia, Pennsylvania

The treatment of hemophilia has evolved from a one-size-fits-all approach to a highly individualized care approach, and it continues to become more patient-centered and specific. This is especially important given that new therapies being introduced have mechanisms of action other than simple factor replacement. Additionally, hemophilia therapies continue to receive approval and enter the market, but what impact do these pipeline therapies have on the standards of care? What strategies can payers implement to manage costs, while also meeting the needs of the patients?

Join this session to discover emerging hemophilia therapies and hemophilia management strategies. This session will also discuss the value of collaboration between payers and patient groups.

Learning Objectives:

At the completion of this activity, participants should be able to:

1. Review emerging hemophilia therapies, their place in therapy, and the impact on standards of care.
2. Discuss best practice strategies for ensuring quality and cost-effective drug therapy in hemophilia.
3. Identify the role of payer and patient group collaboration in the management of hemophilia.